Pulse Biosciences (NASDAQ:PLSE) Upgraded by Wall Street Zen to "Hold" Rating

Key Points

• Wall Street Zen upgraded Pulse Biosciences from “sell” to “hold,” while the broader analyst consensus remains “Moderate Buy” with a $45.25 average price target.
• Analyst views are mixed: Needham initiated coverage with a “buy” rating and a $58 target, while Canaccord raised its target to $43; Weiss Ratings maintained a “sell” rating.
• Pulse Biosciences reported a quarterly loss of $0.36 per share, missing estimates by $0.07, and revenue of $0.43 million, below expectations. The stock recently opened at $47.57, near its 52-week high of $50.90.

Pulse Biosciences (NASDAQ:PLSE - Get Free Report) was upgraded by equities research analysts at Wall Street Zen from a "sell" rating to a "hold" rating in a research note issued on Saturday.

A number of other research analysts have also issued reports on PLSE. Canaccord Genuity Group upped their target price on shares of Pulse Biosciences from $32.00 to $43.00 and gave the company a "buy" rating in a report on Monday, August 10th. Oppenheimer reissued an "outperform" rating on shares of Pulse Biosciences in a research report on Tuesday, July 28th. Weiss Ratings reissued a "sell (d-)" rating on shares of Pulse Biosciences in a research note on Friday, July 17th. Mizuho set a $45.00 target price on shares of Pulse Biosciences in a research report on Monday, August 10th. Finally, Needham & Company LLC started coverage on shares of Pulse Biosciences in a research note on Monday, August 17th. They issued a "buy" rating and a $58.00 target price for the company. Four analysts have rated the stock with a Buy rating and one has given a Sell rating to the company. According to MarketBeat.com, the company currently has an average rating of "Moderate Buy" and a consensus price target of $45.25.

Pulse Biosciences Price Performance

Shares of Pulse Biosciences stock opened at $47.57 on Friday. Pulse Biosciences has a 1 year low of $12.56 and a 1 year high of $50.90. The company has a market capitalization of $3.29 billion, a P/E ratio of -40.31 and a beta of 1.61. The business has a 50 day moving average price of $35.38 and a 200 day moving average price of $27.00.

Pulse Biosciences (NASDAQ:PLSE - Get Free Report) last posted its earnings results on Thursday, August 6th. The company reported ($0.36) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.29) by ($0.07). The company had revenue of $0.43 million during the quarter, compared to analysts' expectations of $0.53 million. Pulse Biosciences had a negative net margin of 6,755.78% and a negative return on equity of 94.42%. As a group, research analysts expect that Pulse Biosciences will post -1.29 EPS for the current fiscal year.

Insider Transactions at Pulse Biosciences

In related news, COO Liane Rae Teplitsky purchased 1,034 shares of the business's stock in a transaction on Friday, August 28th. The shares were bought at an average price of $48.35 per share, with a total value of $49,993.90. Following the completion of the purchase, the chief operating officer directly owned 2,070 shares in the company, valued at approximately $100,084.50. This trade represents a 99.81% increase in their position. The acquisition was disclosed in a filing with the SEC, which is available at this hyperlink. Insiders own 74.00% of the company's stock.

Institutional Trading of Pulse Biosciences

A number of institutional investors and hedge funds have recently made changes to their positions in PLSE. BNP Paribas Financial Markets raised its position in shares of Pulse Biosciences by 63.6% in the 2nd quarter. BNP Paribas Financial Markets now owns 1,749 shares of the company's stock worth $26,000 after buying an additional 680 shares during the period. Osterweis Capital Management Inc. purchased a new stake in Pulse Biosciences during the second quarter valued at about $28,000. Tower Research Capital LLC TRC increased its stake in Pulse Biosciences by 275.0% during the second quarter. Tower Research Capital LLC TRC now owns 2,940 shares of the company's stock worth $44,000 after acquiring an additional 2,156 shares during the last quarter. Russell Investments Group Ltd. increased its stake in Pulse Biosciences by 13.8% during the fourth quarter. Russell Investments Group Ltd. now owns 5,106 shares of the company's stock worth $70,000 after acquiring an additional 619 shares during the last quarter. Finally, The Manufacturers Life Insurance Company purchased a new position in shares of Pulse Biosciences in the 2nd quarter worth about $158,000. 76.95% of the stock is currently owned by institutional investors and hedge funds.

Pulse Biosciences Company Profile

Pulse Biosciences, Inc is a clinical-stage bioelectric medicine company that develops and commercializes medical devices based on its proprietary Tissue NanoPoration (TNP) platform. The company’s core technology, NanoPulse Stimulation (NPS), delivers ultrashort, high-voltage electric pulses to targeted tissue, triggering cellular responses without the thermal damage associated with traditional energy-based devices. Pulse Biosciences focuses on applications in dermatology and aesthetic medicine, where controlled ablation of unwanted lesions is critical.

The company’s flagship product, the CellFX® System, is designed to treat a range of benign and malignant skin lesions, including seborrheic keratosis, non-melanoma skin cancers, and various epidermal and dermal lesions.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.

Continue following MarketBeat

Add MarketBeat as your preferred source on Google to see our latest stories in your feed.

Add As Preferred Source